The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
Official Title:
Study ID: NCT03008304
Brief Summary: The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of pancreatic cancer.
Detailed Description: By enrolling patients with small metastases of pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Minimum Age: 30 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Fuda cancer institute of Fuda cancer hospital, Guangzhou, Guangdong, China